Effectiveness and Safety of BIC/FTC/TAF in Late-Presenting People with HIV-1 Infection DOI Creative Commons
Xiaoyan Yang,

Xiaoxin Xie,

Yanhua Fu

et al.

Open Forum Infectious Diseases, Journal Year: 2024, Volume and Issue: 11(11)

Published: Oct. 18, 2024

Abstract Background The efficacy and safety of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) have been demonstrated in treatment-naive clinical trials. However, real-world evidence for this regimen late-presenting patients with HIV-1 (PWH) is lacking. We investigated the virologic outcomes BIC/FTC/TAF PWH. Methods This retrospective cohort analysis consisted PWH who initiated an antiretroviral between June 2021 2023. Treatment effectiveness, defined as RNA <50 copies/mL, was analyzed. Changes immunologic, metabolic, liver, renal parameters were evaluated. Late-presenting surviving CD4 <200 cells/μL or met criteria AIDS-defining conditions a ranging from 200 to 499 cells/μL. Results A total 130 participants included study. At week 48, 93.8% (122/130) achieved levels copies/mL. increased by 150.0 cells/μL, CD4/CD8 0.16 (P < .001). Sixteen (12.3%) experienced adverse events, 6 (4.6%) drug-related events. None discontinued treatment due either lack effectiveness Conclusions robust suppression tolerability presenting late course HIV infection.

Language: Английский

Effectiveness and Safety of BIC/FTC/TAF in Late-Presenting People with HIV-1 Infection DOI Creative Commons
Xiaoyan Yang,

Xiaoxin Xie,

Yanhua Fu

et al.

Open Forum Infectious Diseases, Journal Year: 2024, Volume and Issue: 11(11)

Published: Oct. 18, 2024

Abstract Background The efficacy and safety of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) have been demonstrated in treatment-naive clinical trials. However, real-world evidence for this regimen late-presenting patients with HIV-1 (PWH) is lacking. We investigated the virologic outcomes BIC/FTC/TAF PWH. Methods This retrospective cohort analysis consisted PWH who initiated an antiretroviral between June 2021 2023. Treatment effectiveness, defined as RNA <50 copies/mL, was analyzed. Changes immunologic, metabolic, liver, renal parameters were evaluated. Late-presenting surviving CD4 <200 cells/μL or met criteria AIDS-defining conditions a ranging from 200 to 499 cells/μL. Results A total 130 participants included study. At week 48, 93.8% (122/130) achieved levels copies/mL. increased by 150.0 cells/μL, CD4/CD8 0.16 (P < .001). Sixteen (12.3%) experienced adverse events, 6 (4.6%) drug-related events. None discontinued treatment due either lack effectiveness Conclusions robust suppression tolerability presenting late course HIV infection.

Language: Английский

Citations

2